Related Experiment Video
Updated: Jun 24, 2025
05:58
Measuring Relative Insulin Secretion using a Co-Secreted Luciferase Surrogate
Published on: June 25, 2019
7.4K
Comparing Insulin Prices in the United States to Other Countries: Updated Results Using 2022 Data
Rand Health Quarterly
|June 10, 2024
Summary
US insulin prices are significantly higher than in other developed nations. This study compares US and international insulin prices, revealing substantial cost disparities for patients and healthcare systems.
Area of Science:
- Health Economics
- Pharmaceutical Pricing
- Public Health Policy
Background:
- Manufacturer list prices for insulin have escalated in the US over the last decade.
- Previous research highlighted US-international insulin price discrepancies.
Purpose of the Study:
- To compare US insulin prices with those in 33 Organisation for Economic Co-operation and Development (OECD) countries.
- To analyze price differences using both gross and net manufacturer prices.
Main Methods:
- Employed a price index approach for comparing insulin costs.
- Examined all insulins and specific insulin categories.
- Included data on US pharmacy prices and estimated net prices after rebates.
Main Results:
- US insulin prices are substantially higher compared to 33 OECD countries.
- Price disparities persist across different insulin types and pricing methods (gross vs. net).
Conclusions:
- The US faces significantly higher insulin costs than comparable nations.
- Policy interventions may be needed to address the high cost of insulin in the United States.
Related Concept Videos
01:25Insulin: Biosynthesis, Chemistry, and Preparation
372
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
372
01:27Insulin Formulations: Types and Delivery
190
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
190
01:16Insulin: Dosing Regimen and Adverse Effects
166
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
166
01:28Insulin: The Receptor and Signaling Pathways
1.2K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
1.2K
01:24Glucagon-like Receptor Agonists
316
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
316
01:06Oral Hypoglycemic Agents: Glinides
152
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
152